Vertex touts early uptake of Journavx, plots $1B+ sales trajectory for Casgevy

As the pharmaceutical industry struggles to make gene therapies profitable, Vertex Pharmaceuticals is predicting that its one-time blood disorder treatment is on track to be a multi–billion-dollar product, after taking a 'slow but steady' approach with the rollout of Casgevy (exagamglogene autotemcel).